GAM Holding AG Cuts Stake in Charles River Laboratories Intl. Inc (CRL)

Share on StockTwits

GAM Holding AG lessened its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 51.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,856 shares of the medical research company’s stock after selling 3,048 shares during the quarter. GAM Holding AG’s holdings in Charles River Laboratories Intl. were worth $321,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CRL. Signaturefd LLC acquired a new position in Charles River Laboratories Intl. in the 1st quarter valued at about $105,000. Adviser Investments LLC acquired a new position in Charles River Laboratories Intl. in the 1st quarter valued at about $152,000. CIBC Private Wealth Group LLC acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at about $212,000. Visionary Asset Management Inc. acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at about $214,000. Finally, Intrust Bank NA acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at about $232,000. 97.76% of the stock is owned by institutional investors and hedge funds.

NYSE CRL opened at $125.50 on Friday. Charles River Laboratories Intl. Inc has a 12 month low of $96.70 and a 12 month high of $130.66. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48. The stock has a market cap of $5.97 billion, a PE ratio of 21.80, a P/E/G ratio of 1.57 and a beta of 0.65.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, beating the Zacks’ consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The company had revenue of $585.30 million during the quarter, compared to the consensus estimate of $570.65 million. During the same quarter in the prior year, the company posted $1.29 EPS. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. analysts expect that Charles River Laboratories Intl. Inc will post 5.88 earnings per share for the current fiscal year.

In other news, CEO James C. Foster sold 5,005 shares of the business’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $110.80, for a total transaction of $554,554.00. Following the completion of the sale, the chief executive officer now owns 296,676 shares in the company, valued at approximately $32,871,700.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George Massaro sold 300 shares of the business’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $115.55, for a total value of $34,665.00. Following the sale, the director now owns 14,037 shares of the company’s stock, valued at approximately $1,621,975.35. The disclosure for this sale can be found here. Insiders have sold a total of 37,324 shares of company stock valued at $4,504,045 in the last quarter. Company insiders own 2.10% of the company’s stock.

CRL has been the subject of several analyst reports. Raymond James raised shares of Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 target price for the company in a research note on Thursday, August 23rd. TheStreet raised shares of Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research note on Thursday, May 10th. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th. SunTrust Banks upped their price objective on shares of Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Royal Bank of Canada raised shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price objective for the company in a research note on Tuesday, July 17th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Charles River Laboratories Intl. presently has an average rating of “Buy” and a consensus target price of $125.40.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply